Table 2.
Potential clinical trial vaccine candidates against SARS-CoV, MERS-CoV, and SARS-CoV2.
| vaccine type | Antigen target | Administration route | The clinical trial dose regimen | Phase | Reference |
|---|---|---|---|---|---|
| Potential vaccine candidates (clinical trial) cf against SARS-CoV | |||||
| DNA vaccine | S protein | IM | 3 dose vaccination | Phase I | [184] |
| S protein | EP | Three-injection vaccination regimen (0.67, 2, and 3 mg DNA/dose) followed by electroporation | Phase I | Id.NCT02670187 | |
| S protein | IM | 5 × 10^9 and 2.5 × 10^9 vp ChAdOx1 | Phase I | Id.NCT03399578 | |
| Potential vaccine candidates (clinical trial) against MERS | |||||
| DNA vaccine | S protein | IM | 0·67 mg, 2 mg, or 6 mg GLS-5300 intramuscular injection at baseline, week 4, and week 12 followed immediately by co-localized intramuscular electroporation | Phase I | [191] |
| Potential vaccine candidates (clinical trial) against SARS-CoV2 | |||||
| Inactivated whole virus | SARS-Alum | IM | 2 doses: 0, 14 days | Phase I/II |
NCT04383574 NCT04342583 |
| SARS | IM | 2 doses (0,14 or 0,21 days) | Phase I/II | ChiCTR2000031809 | |
| SARS | IM | 2 doses (0,14 or 0,21 days) | Phase I/II | ChiCTR2000032459 | |
| SARS | IM | 2 doses (0, 28 days) | Phase I/II | NCT04412538 | |
| SARS-CoV-2 (PiCoVacc mixed with alum adjuvants) | IM | various doses | Pre-clinical | [121] | |
| DNA vaccine | S protein | ID followed by EP | Two ID injections of 1.0 mg (total 2.0 mg per dosing visit) | Phase I | [200] |
| mRNA vaccine | S protein | IM | 0.5 ml [mL] of mRNA-1273 on Days 1 and 29 in the deltoid muscle and will be followed through 12 months post-second vaccination (Day 394) | Phase I | [174] |
| Recombinant SARS-CoV-2 (Adenovirus Type 5 Vector) | Adenovirus Type 5 Vector | IM | Dose-escalating phase I clinical trial in healthy 18 to 60 years of age (5E10, 1E11, 1.5 E11 VP Ad5-nCoV at 18 to 60 years old) on Days 1 in the deltoid muscle. 1 × 10^11vp, 5 × 10^10vp, and placebo of Ad5-nCoV administered through 1.0 mL intramuscular injection in the deltoid muscle on Day 0. A total of 96 healthy adult volunteers will be vaccinated in phase I stepwise according to the dose-escalation design from the younger adults (18 to <55) to the older adults (65 to <85). There are 2 dosage levels used in this phase: 5E10vp and 10E10vp, and 2 dose schedules. |
*Phase I **Phase II ***Phase I/II |
Id. CT04313127 Id. NCT04341389 Id.CT04398147 |
*CanSino Biological Incorporation, **Beijing Institute of Biotechnology, **Canadian Center for Vaccinology.